Key Highlights

  • Shares are trading down 2.27% at $29.98 versus a prior close of $30.67.
  • Adjusted EPS of $0.87 topped the roughly $0.73 consensus.
  • Full-year Revenue guidance was raised to $62 billion to $64 billion.

Pfizer (NYSE:PFE) shares are trading down 2.27% at $29.98 today even after a third-quarter beat and higher 2026 guidance, as investors appear to sell into strength after a roughly 12% run to a 52-week high of $31.05. The stock sits above its average analyst target near $29 and well above its 52-week low of $23.62, and healthcare is lagging while the broader market is mixed ahead of the midterm election results.

Pfizer is a New York-based global biopharmaceutical company founded in 1849 that discovers, develops and manufactures medicines and vaccines across oncology, internal medicine, vaccines, inflammation and immunology, rare disease and hospital care. Its portfolio includes Eliquis, the Prevnar family, Comirnaty, Paxlovid, Ibrance and Xtandi, and the company has roughly 75,000 employees.

Q3 Beat Led by Eliquis and Launched Products

Revenue was $16.6 billion, against estimates near $15.9 billion, with non-COVID products up 7% operationally and launched and acquired products up 32% to $3.8 billion. Adjusted EPS of $0.87, including a $0.10 Innovent charge, beat the $0.73 consensus, with adjusted gross Margin at 77% and adjusted Operating Margin at 36%. Eliquis grew 25% and Padcev grew 55%.

Investors are also weighing Paxlovid and Comirnaty declines, softer Prevnar sales, the upcoming Ibrance and Eliquis Patent expirations and a delay of mevrometostat Phase 3 data to the first quarter of 2027. Pfizer also named Cecile Guegan as permanent CFO.

Guidance Raised With 2027 Headwinds Flagged

Full-year revenue guidance was raised by $1.5 billion at the midpoint to $62 billion to $64 billion, and adjusted EPS guidance was narrowed to $2.95 to $3.05, up $0.10 at the midpoint despite the Innovent impact. R&D expense is expected at $10.8 billion to $11.8 billion, COVID product revenue at about $4 billion and adjusted gross margin in the mid-70s percent range.

Cost programs remain on track to deliver nearly all of the $7.2 billion in net savings by the end of 2026, with a further $2.5 billion targeted for 2027 to 2029. Leverage ended at 2.6x and Business development capacity is about $6 billion. Full 2027 guidance is due in mid-December, with headwinds from Eliquis loss of exclusivity, the IRA and 340B offset by launched and acquired products.

Pipeline Milestones and an Obesity Push Round Out the Story

Pipeline progress included positive Phase 3 data for Lexfio in multiple myeloma, with MM5 data due before year-end. Phase 2 data are expected for atirmociclib, sigvotatug, tonevetamig and the trispecific antibody tilrekimig, and PCV25 pediatric results were strong. Mevrometostat Mephro 1 now reads out in the first quarter of 2027 and Mephro 2 in the fourth quarter of 2027.

In obesity, Pfizer plans 10 active or planned Phase 3 trials in 2026, with first potential approvals for monthly GLP-1 MET-097i in 2028 and Phase 2b amylin data in the second half of 2027. Management also said it believes street estimates for Nurtec and Lexfio are too low. Merck (NYSE:MRK) was lowered by DZ Bank earlier in the week and Amgen (NASDAQ:AMGN) reports after the close.

December Guidance Is the Next Big Marker

With a 5.75% Dividend Yield and a stock near its 52-week high, the next key event is the mid-December guidance update for 2027. Mevrometostat readouts in 2027 follow.